Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20420527&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
INGN-225: a dendritic cell-based p53 vaccine (Ad p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect Chiappori AA; Soliman H; Janssen WE; Antonia SJ; Gabrilovich DIExpert Opin Biol Ther 2010[Jun]; 10 (6): 983-91IMPORTANCE OF THE FIELD: Novel approaches are needed for patients with small cell lung cancer (SCLC), as response after relapse is poor with standard therapies. p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for their recognition by p53-specific cytotoxic T cells. AREAS COVERED IN THIS REVIEW: We describe the characteristics and manufacturing of INGN-225, a p53-modified adenovirus-tranduced dendritic cell vaccine, and review available data, to understand INGN-225's role in SCLC treatment. We discuss our pre-clinical, early Phase I/II, and ongoing randomized Phase II studies. WHAT THE READER WILL GAIN: INGN-225 was well tolerated (all toxicities |*Immunotherapy[MESH]|Animals[MESH]|Cancer Vaccines/administration & dosage/adverse effects/*therapeutic use[MESH]|Clinical Trials, Phase I as Topic[MESH]|Clinical Trials, Phase II as Topic[MESH]|Dendritic Cells/*immunology[MESH]|Humans[MESH]|Lung Neoplasms/*immunology/*therapy[MESH]|Randomized Controlled Trials as Topic[MESH]|Small Cell Lung Carcinoma/*immunology/*therapy[MESH]|Tumor Suppressor Protein p53/*immunology[MESH] |
